Adaptive Glucokinase Activator Systems for High-Risk Diabetes Management

Publication ID: 24-11857536_0004_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Adaptive Glucokinase Activator Systems for High-Risk Diabetes Management,” Published Technical Disclosure No. 24-11857536_0004_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857536_0004_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,536.

Summary of the Inventive Concept

This inventive concept adapts glucokinase activators for treating diabetes in renally impaired subjects in specialized scenarios, such as extreme weather conditions, high-security environments, and disaster relief situations.

Background and Problem Solved

The original patent addresses glucokinase-mediated disorders in renally impaired subjects, but lacks consideration for unique operational environments. This inventive concept addresses the specific problem of managing diabetes in high-risk situations, where traditional treatments may be insufficient or impractical.

Detailed Description of the Inventive Concept

The inventive concept encompasses four specialized systems and methods: (1) a wearable-based system for real-time glucose monitoring and healthcare provider communication, (2) a satellite-based emergency medical assistance system for extreme weather conditions, (3) a portable, biometrically authenticated device for high-security environments, and (4) a continuous glucose monitoring and alert system for preventing hypoglycemia. These adaptations ensure the safe and effective treatment of diabetes in renally impaired subjects, even in challenging operational environments.

Novelty and Inventive Step

The new claims introduce novel combinations of glucokinase activators with specialized technologies, such as wearable devices, satellite-based communication systems, biometric authentication, and continuous glucose monitoring. These integrations provide a non-obvious solution for managing diabetes in high-risk situations, distinguishing the inventive concept from the original patent.

Alternative Embodiments and Variations

Alternative embodiments may include integrating glucokinase activators with other specialized technologies, such as artificial intelligence-powered health analytics, telemedicine platforms, or environmental sensors. Variations may also include adapting the inventive concept for other high-risk populations, such as those with cardiovascular disease or chronic obstructive pulmonary disease.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the healthcare industry, particularly in the areas of diabetes management, emergency medical response, and high-security healthcare. Target markets may include healthcare providers, pharmaceutical companies, and medical device manufacturers.

Original Patent Information

Patent NumberUS 11,857,536
TitleGlucokinase activator for treating diabetes with renal impairment
Assignee(s)HUA Medicine (Shanghai) Ltd.